Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 6/20 | 0.76 |
| ▸ | MAOB | P27338 | 6/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.76 |
| ▸ | SDHA | P31040 | 2/20 | 0.76 |
| ▸ | LMNA | P02545 | 1/20 | 0.76 |
| ▸ | CALML3 | P27482 | 1/20 | 0.76 |
| ▸ | F10 | P00742 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8308403 | 1.00 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL21968386 | 0.94 | MAOA (0.68) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7955698 | 0.91 | MAOB (0.66) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7955695 | 0.91 | MAOB (0.66) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10152612 | 0.90 | MAOB (0.64) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL10152654 | 0.90 | MAOA (0.63) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18408933 | 0.90 | MAOB (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL18410708 | 0.89 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3207960 | 0.89 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3207948 | 0.89 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0717738-B1 | SUBSTITUTED OXAZINE AND THIAZINE OXAZOLIDINONE ANTIMICROBIALS | UPJOHN CO (US) | 1999-10-20 | — | — | EP | claimed |
| EP-3932917-A2 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | The Global Alliance for TB Drug Development, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC (US) | 2020-05-14 | — | — | US | disclosed |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. | 2018-06-28 | — | — | US | disclosed |
| WO-2017015106-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THE GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179168-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
| US-20200148651-A1 | SUBSTITUTED PHENYLOXAZOLIDINONES FOR ANTIMICROBIAL THERAPY | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
| US-10550092-B2 | Substituted phenyloxazolidinones for antimicrobial therapy | THPO, TBCD, OXA1L | MAOA 2234/4885MAOB 1541/4885PTGS1 1413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.